Talphera (NASDAQ:TLPH – Get Free Report) and ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.
Analyst Ratings
This is a breakdown of current ratings for Talphera and ANI Pharmaceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Talphera | 1 | 1 | 2 | 0 | 2.25 |
| ANI Pharmaceuticals | 0 | 4 | 3 | 0 | 2.43 |
Talphera currently has a consensus price target of $3.00, suggesting a potential upside of 177.78%. ANI Pharmaceuticals has a consensus price target of $99.60, suggesting a potential upside of 35.34%. Given Talphera’s higher probable upside, equities analysts plainly believe Talphera is more favorable than ANI Pharmaceuticals.
Insider & Institutional Ownership
Earnings and Valuation
This table compares Talphera and ANI Pharmaceuticals”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Talphera | $1,000.00 | 56,058.48 | -$14.29 million | ($0.27) | -4.00 |
| ANI Pharmaceuticals | $978.38 million | 1.73 | $78.34 million | $4.64 | 15.86 |
ANI Pharmaceuticals has higher revenue and earnings than Talphera. Talphera is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Talphera has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500. Comparatively, ANI Pharmaceuticals has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500.
Profitability
This table compares Talphera and ANI Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Talphera | N/A | -87.28% | -51.36% |
| ANI Pharmaceuticals | 11.07% | 27.37% | 10.47% |
Summary
ANI Pharmaceuticals beats Talphera on 11 of the 14 factors compared between the two stocks.
About Talphera
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Receive News & Ratings for Talphera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talphera and related companies with MarketBeat.com's FREE daily email newsletter.
